Aktuelle medikamentöse Therapie des nichtkleinzelligen Lungenkarzinoms

Das nichtkleinzellige Lungenkarzinom (NSCLC) galt lange als schwer therapierbar. In den letzten 3 Jahren hat sich dieses Bild durch den breiten Einsatz der Immuntherapie sowie zielgerichtete Therapieansätze erheblich gewandelt. Dieser Beitrag gibt eine Übersicht.

Publication History

Article published online:
01 April 2020

• Literatur

• 1 Kraywinkel K, Schönfeld I. Epidemiologie des nicht-kleinzelligen Lungenkarzinoms in Deutschland. Onkologe 2018; 24: 946-951
• 2 Zhang YL, Yuan JQ, Wang KF. et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016; 7: 78985-78993
• 3 Joshi A, Zanwar S, Noronha V. et al. EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?. Onco Targets Ther 2017; 10: 1859-1863
• 4 Sholl LM, Aisner DL, Varella-Garcia M. et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol 2015; 10: 768-777
• 5 Jucker M, Gunther A, Gradl G. et al. The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk Res 1994; 18: 7-16
• 6 Schildhaus HU, Schultheis AM, Ruschoff J. et al. MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. Clin Cancer Res 2015; 21: 907-915
• 7 Yoshida A, Tsuta K, Watanabe S. et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 2011; 72: 309-315
• 8 Bergethon K, Shaw AT, Ou SH. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-870
• 9 Antonia SJ, Villegas A, Daniel D. et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 379: 2342-2350
• 10 Reck M, Rodríguez-Abreu D, Robinson AG. et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016; 375: 1823-1833
• 11 Ghandi L, Rodríguez-Abreu D, Gadgeel S. et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378: 2078-2092
• 12 West H, McCleod M, Hussein M. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 924-937
• 13 Socinski MA, Jotte RM, Cappuzzo F. et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 2018; 378: 2288-2301
• 14 Paz-Ares L, Luft A, Vicente D. et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018; 379: 2040-2051
• 15 Soria JC, Ohe Y, Vansteenkiste J. et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378: 113-125
• 16 Peters S, Camidge DR, Shaw AT. et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377: 829-838
• 17 Garon EB, Hellmann MD, Costa EC. et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. J Clin Oncol 2019; 37 (suppl.): LBA9015